Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

esketamine

- PMLiVE

Lundbeck sways NICE with new Brintellix data

Final draft guidance now backs the major depressive disorder drug

- PMLiVE

J&J’s share buyback ‘doesn’t prevent acquisitions’

Comes as company reports 7.4% decrease in sales

- PMLiVE

J&J’s Invokana receives new FDA safety warning

Additional trial data highlights bone problems

- PMLiVE

JWT turns to Oscar nominee for Listerine campaign

Produces short online film and app for J&J's mouthwash brand

- PMLiVE

US filing aims to elevate Brintellix above its competition

Drug looking for an edge in the highly competitive major depressive disorder market

- PMLiVE

Lundbeck and Otsuka’s Rexulti set for August launch in US

Follows the antipsychotic drug's FDA approval on Friday

- PMLiVE

HIV vaccine from J&J starts human trials

Vaccine provided complete protection in primates for similar infection 

- PMLiVE

J&J and LDC to join forces on unmet medical needs

Collaboration will aim to find and accelerate new potential treatments

- PMLiVE

J&J signs $1bn deal with Achillion for hepatitis C therapies

Will license three candidates from Achillion Pharma

- PMLiVE

FDA approves J&J’s schizophrenia drug Invega Trinza

New version of Invega is the first treatment for the condition to require only four doses a year

- PMLiVE

J&J takes external advice on compassionate use

Drugmaker will run a pilot for a review of one late-stage project

IBM sets up Watson Health unit to advance its data ambitions

Will also partner with Apple, J&J and Medtronic and acquire two big data companies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links